Loading...
XNYS
BIO
Market cap8.57bUSD
Dec 05, Last price  
317.69USD
1D
-0.74%
1Q
7.53%
Jan 2017
74.29%
Name

Bio Rad Laboratories Inc

Chart & Performance

D1W1MN
XNYS:BIO chart
P/E
P/S
3.34
EPS
Div Yield, %
Shrs. gr., 5y
-1.34%
Rev. gr., 5y
2.11%
Revenues
2.57b
-3.92%
1,180,985,0001,273,930,0001,461,052,0001,764,365,0001,784,244,0001,927,118,0002,073,529,0002,069,235,0002,132,694,0002,175,044,0002,019,441,0002,068,172,0002,160,153,0002,290,109,0002,311,659,0002,545,626,0002,922,545,0002,802,249,0002,671,262,0002,566,500,000
Net income
-1.84b
L+189.37%
81,553,000103,263,00092,994,00089,510,000144,620,000185,490,000178,223,000169,234,00077,790,00088,845,000113,093,00028,125,000114,740,000360,996,0001,758,675,0003,814,229,0004,254,257,000-3,627,535,000-637,324,000-1,844,200,000
CFO
455m
+21.41%
108,284,000118,229,000191,580,000191,371,000325,074,000225,909,000259,816,000278,898,000175,476,000273,312,000186,210,000216,433,000103,885,000285,494,000457,897,000575,328,000656,521,000194,447,000374,943,000455,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
IPO date
Mar 17, 1980
Employees
8,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT